Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study.
This trial investigated the tolerability and effect of modified citrus pectin (Pecta-Sol) in 13 men with prostate cancer and biochemical prostate-specific antigen (PSA) failure after localized treatment, that is, radical prostatectomy, radiation, or cryosurgery. A total of 13 men were evaluated for tolerability and 10 for efficacy. Changes in the prostate-specific antigen doubling time (PSADT) of the 10 men were the primary end point in the study. We found that the PSADT increased (P-value<0.05) in seven (70%) of 10 men after taking MCP for 12 months compared to before taking MCP. This study suggests that MCP may lengthen the PSADT in men with recurrent prostate cancer.
Guess
B W
BW
Prostate Oncology Specialist, Marina del Rey, California 90292, USA. Brad@prost8cancer.com
Scholz
M C
MC
Strum
S B
SB
Lam
R Y
RY
Johnson
H J
HJ
Jennrich
R I
RI
D000368:Aged; D002957:Citrus; D006801:Humans; D008297:Male; D008875:Middle Aged; D010368:Pectins / Q000009:adverse effects / Q000737:chemistry* / Q000627:therapeutic use*; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood*; D013739:Testosterone / Q000097:blood
D013739:Testosterone; D010368:Pectins; D017430:Prostate-Specific Antigen